Skip to main content
. 2021 Sep 22;9(2):e00484-21. doi: 10.1128/Spectrum.00484-21

FIG 7.

FIG 7

Oral administration of different forms of A. muciniphila could normalize the fecal targeted bacteria composition, improve the intestinal permeability, modulate inflammatory responses, and subsequently prevent liver injury in the HFD/CCl4 mice model. Following the improvement of intestinal and liver histopathology, HFD/CCl4-induced kidney damage and adipose tissue inflammation were also ameliorated by different A. muciniphila treatments.